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The aim of this study was to investigate the transforming growth factor (TGF)-β1/mothers against 
decapentaplegic homolog (Smad) signaling pathway associated with airway reconstruction in chronic 
asthmatic rats by studying mRNA and protein expression. Twenty-four (24) Sprague-Dawley rats were 
randomly divided into two groups: a normal control group treated with 0.9% saline and an OVE+ALU 
group treated with a mixture of 10% ovalbumin and 10% aluminum hydroxide. Hematoxylin-eosin (HE) 
staining was used to observe the pathomorphological changes, and the locations of TGF-β and Smad 2, 
4 and 7 were determined by immunohistochemistry. The mRNA expression of TGF-β and Smad 2, 4 and 
7 was determined by real time-polymerase chain reaction (RT-PCR). The protein expression of TGF-β 
was determined by enzyme-linked immunosorbent assay (ELISA), whereas that of Smad 2, 4 and 7 was 
determined by western blotting. HE staining revealed that the OVE+ALU group displayed obvious signs 
of bleeding and expansion of lung alveolar and inflammatory cells. Immunofluorescence showed that 
TGF-β and Smad 2, 4 and 7 proteins were located in the bronchial wall or alveolar wall. RT-PCR showed 
that mRNA expression of Smad 2 was significantly higher in the OVE+ALU group than in the control 
group (P < 0.05) and that mRNA expression of Smad 7 was significantly lower in the OVE+ALU group 
than in the control group (P < 0.05). There was no significant difference in Smad 4 mRNA expression 
between the two groups (P > 0.05). Western blotting showed that TGF-β1 and Smad 2 protein 
expression was significantly higher in the OVE+ALU group than in the control group (P < 0.05), 
whereas, in contrast, Smad 4 and 7 protein expression was significantly lower in the OVE+ALU group 
than in the control group (P < 0.05). The process of chronic asthma rats, TGF-β and Smad 2, 4 and 7 
expressions were changeable, thus the TGF-β/Smad signaling pathway may play a role in chronic 
asthma. 
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Abbreviation: TGF, Transforming growth factor. 
that is highly prevalent worldwide, affecting approximately 
300 million individuals of all ages (World Health 
Organization, 2007). The incidence of chronic asthma 
has increased in recent years due to environmental 
pollution caused by car exhausts and lifestyle changes. 
The concept of asthma control includes clinical and 





awakenings, use of rescue medication, activity limitation, 
and pulmonary function (Global Initiative for Asthma, 
2009). Asthma has multiple negative influences on the 
patient’s quality of life. Although, majority of asthma 
patients can obtain the targeted level of control, some 
patients will not achieve control even with the best 
therapy (Nathan, et al., 2004).  
Patients who do not reach an acceptable level of 
control with the use of reliever medication plus two or 
more controllers can be considered to have difficult-to-
treat asthma (Wenzel, 2005). 
Asthma is a chronic complex inflammatory airway dis-
order characterized by variable degrees of recurring 
symptoms of airflow obstruction and bronchial hyper 
responsiveness (National Institute of Health, 2007), and 
airway reconstruction is one of the pathophysiological 
characteristics of chronic asthma. The performances of 
the airway re-established include thickening of smooth 
muscle and the airway basal surface, deposition of 
extracellular matrix, infiltration of inflammatory cells, 
overgrowth of glandular organs and hypertrophy, which 
can lead to airway hyper-reactivity, irreversible airflow 
blockage, etc. Remodeling processes in asthma result 
from highly complex and poorly defined interactions 
between inflammatory and resident structural cells 
(James, 2005). Therefore, the identification of the mole-
cular pathways involved in the crosstalk between these 
cells is a prerequisite for the development of novel 
therapy to control airway remodeling. 
Previous studies (Chu et al., 1998) have demonstrated 
that the transforming growth factor (TGF)-β/ mothers 
against decapentaplegic homolog (Smad) signaling path-
way is very important in airway re-established in chronic 
asthma. TGF-β is a founding member of the TGF-β super 
family, including activins inhibiting growth and differen-
tiation factors, and bone morphogenetic proteins. TGF-β1 
and its isoforms (TGF-β2 and TGF-β3) are synthesized 
by a variety of cells including all cell types, and are 
secreted as latent precursors (latent TGF-β1) complexed 
with latent TGF-β binding proteins (LTBP) (Wang et al., 
2005; Roberts, 1998). Active TGF-β then binds its recep-
tors and functions to exert its biological and pathological 
activities via Smad-dependent and independent signaling 
pathways (Derynck and Zhang, 2003).  
The Smad complexes then accumulate in the nucleus 
to regulate target gene expression cooperatively with 
other transcription factors in a cell context-dependent 
manner (Feng and Derynck, 2005; Siegel and Massague, 
2003; Moustakas et al., 2001).  
The phosphorylated Smad 2 and 3 then bind to Smad 4 
and form the Smad complex, which translocate into the 
nucleus and regulates the target gene transcription, 
including Smad 7. Smad 7 is an inhibitory Smad that 
functions to block Smad 2/3 activation by degrading the 
TβRI (Hui, 2011).  
This study aimed to determine whether airway recon-
struction involves changes in the TGF-β/Smad signaling 
pathway. 








Specific pathogen-free Sprague-Dawley (SPF SD) male rats, 
weighing 180 to 200 g were obtained from the Experimental Animal 





Twenty-four (24) healthy SPF SD male rats were randomly divided 
into two groups: a normal control group (n = 12) and an OVE+ALU 
experimental group (n = 12). Each rat in the control group received 
subcutaneous injections of 1 ml of 0.9% saline every day for two 
weeks, whereas the rats in the OVE+ALU group were injected with 
1 ml of a solution of ovalbumin and aluminum hydroxide dissolved 
in 0.9% saline (ova:alu:saline = 1:1:8, v/v). After two weeks, all the 
rats were sprayed with 2% ovalbumin aerosol in a sealed container 
every other day for two weeks to induce asthma. Except for the 





Lung tissues taken from each rat were fixed in 15% buffered 
paraformaldehyde and dehydrated in a graded alcohol series. The 
specimens were then embedded in paraffin blocks and cut into 5 
µm-thick sections. The sections were stained with hematoxylin-
eosin (HE). Pathological examinations were performed by a 





Fresh lung tissues taken from rats anesthetized with ether were 
embedded in buffer containing 4% paraformaldehyde, 20% sucrose 
and 30% sucrose. The specimens were then cut into 25 µm-thick 
cryostat sections and mounted on Superfrost plus slides or gelatin-
coated slides. The slides were stored at -20°C until needed. Before 
staining, slides were warmed at room temperature for 30 min and 
fixed in ice-cold acetone for 5 min, followed by air-drying for 30 min. 
The following antibodies were used: monoclonal anti-TGF-β 
antibody (1:1000 in phosphate buffered saline (PBS)), monoclonal 
anti-human Smad 7 antibody (1:1000), monoclonal rabbit anti-
Smad 2 antibody and monoclonal rabbit anti-Smad 4 antibody 
(1:1000). After reacting with the secondary peroxidase-conjugated 
antibody and washed in PBS, the antibody complex was visualized 
using 3,3-diaminobenzidine. The specimens were observed under a 
regular light microscope.  
 
 
Reverse transcriptase polymerase chain reaction 
 
Total RNA was isolated using a high pure RNA isolation kit 
according to the manufacturer’s instructions. Contaminating DNA 
was removed by treating the samples with RNase-free DNase. One 
hundred micrograms of total RNA was reverse-transcribed and 
subjected to polymerase chain reaction (PCR) with an initial step of 
94°C for 2 min followed by 40 cycles of 94°C for 15 s, 58°C for 30 s 
and 72°C for 30 s, and a final extension at 72°C for 10 min. The 
following primers were used: rat TGF-β forward, 5′-
TACAGGGCTTTCGCTTCAGT-3′ and reverse, 5′-TGGTTGTAG-
AGGGCAAGGAC-3′; Smad 2 forward, 5′-ATACCCACTCCATTC-
CAG-3′ and reverse, 5′-CACTATCACTTAGGCACTGG-3′; Smad 4 
forward, 5′-AGGTGGCTGGTCGGAAAG-3′ and reverse, 5′-












TTGGTGGATGTTGGATGGTT-3′; Smad 7 forward, 5′-GGCATA-
CTGGGAGGAGAAGA-3′ and reverse, 5′-CTGTTGAAGATGA-
CCTCCTCCAGC-3′; glyceraldehyde 3-phosphate dehydrogenase 
(GADPH) forward, 5′-CCGTAAAGACCTCTATGCCAACA-3′ and 
reverse, 5′-GGACTCATCGTACTCCTGCT-3′. 
All samples were subjected to reverse transcriptase (RT)-PCR 
along with the housekeeping gene GAPDH as an internal standard, 
which was amplified using the following primer sequences: GAPDH 
forward, 5′-CCGTAAAGACCTCTATGCCAACA-3′ and reverse, 5′-
GGACTCATCGTACTCCTGCT-3′. Reaction specificity was 
confirmed by gel electrophoresis of products after RT-PCR and 
melting curve analysis. Ratios for Smad/GAPDH mRNA were 






Total protein was extracted from lung tissues and quantified using a 
bicinchoninic acid protein concentration assay kit. Samples (50 µg) 
were fractionated on a 12% sodium dodecyl sulphate-poly-
acrylamide gel electrophoresis (SDS-PAGE) separating gel using a 
Bio-Rad electrophoresis apparatus (Bio-Rad Laboratories, 
Hercules, CA, USA). After transferring proteins onto nitrocellulose 
membrane, the blots were probed with a mouse monoclonal 
antibody to Smad 2 (CST, 1:1000 dilution), a mouse monoclonal 
antibody to Smad 4 (R&D,1:1000 dilution) and a mouse monoclonal 
antibody to Smad 7 (Santa Cruz,1:1000 dilution). The secondary 
antibody was goat anti-mouse IgG (1:1000), which was diluted in 






Data were calculated as the mean ± SD and the groups were 
compared using one-way analysis of variance (ANOVA). Statistical 





Histology of lung tissues in chronic asthmatic rats 
 
We examined the effects of OVE+ALU-induced chronic 
asthma on lung tissue using HE staining. The histology of 
the HE-stained tissues showed a marked alteration in the 




Immunohistochemistry of lung tissues in chronic 
asthmatic rats 
 
Figure 2 shows the immunohistochemistry of TGF-β and 
Smads in the lung tissues of chronic asthmatic rats. 
 
 
mRNA expression of TGF-β and Smads in chronic 
asthma 
 
mRNA expression of TGF-β1 and Smad 2 were 
significantly increased in the experimental group when 
compared with the control group (P < 0.05). There was no 
significant difference in Smad 4 mRNA expression 
between the control group and the experimental group. 
mRNA expression of Smad 7 decreased significantly in 
the experimental group when compared with the control 
group (P < 0.05) (Table 1 and Figure 3). 
 
 
TGF-β and Smad protein expression in chronic 
asthma 
 
Expression of TGF-β in lung tissue increased significantly 
in the experimental group, as measured by enzyme-
linked immunosorbent assay (ELISA) (P < 0.05). 
Expression of Smad 2, 4 and 7 in lung tissue increased 
significantly in the experimental group as detected by 





The TGF-β family of cytokines encompasses a large 
number of versatile poly-peptide growth factors regulating  
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Figure 2. Immunohistochemistry of TGF-β and Smads in the lung tissues of 
chronic asthmatic rats. A, Smad 2 (control group); B, Smad 2 (OVE+ALU group); 
C, Smad 4 (control group); D, Smad 4 (OVE+ALU group); E, Smad 7 (control 
group); F, Smad 7 (OVE+ALU group); G, TGF-β (normal group); H, TGF-β 
(OVE+ALU group). The results show that TGF-β and Smad 2, 4, and 7 were all 
expressed on the bronchial or alveolar wall. All groups are different about 





a multitude of cellular processes in almost every aspect 
of cellular function. TGF-β is a widely acknowledged 
multifunctional factor that can regulate cell growth, 
differentiation, apoptosis and synthesis of extracellular 
matrix (ECM) (Zhang et al., 2009). TGF-β mediates 
biological effects through the TGF-β1/Smad signaling 
pathway. Much has been known about the TGF-β 
signaling pathway since the discovery of Smads 15 years 
ago; remarkable progress has been made during the past 
few years in revealing details of different regulatory 
mechanisms that afford a full range of control of the 
biological functions of the TGF-β (Ying and  Zhang, 2011).  




Table 1. Expression of TGF-β1 and Smad 2, 4 and 7 mRNA (mean ± SD, n = 6). 
 
Group TGF-β/GAPDH Smad 2/GAPDH Smad 4/GAPDH Smad 7/GAPDH 
Normal control 0.50 ± 0.31 0.74 ± 0.22 0.81 ± 0.22 1.05 ± 0.09 
Experimental 1.09 ± 0.31* 1.30 ± 0.13* 0.77 ± 0.20 0.55 ± 0.23* 
 







Figure 3. mRNA expression of TGF-β and Smads in chronic asthma in the lung tissues of chronic asthmatic rats. A, TGF-
β1; B, Smad 2; C, Smad 4 control group; D, Smad 7 OVE+ALU group; E, GAPDH; lanes 1, 3, 5 and 7 (normal control 
group); 2 lanes, 4, 6, 8, 9 (OVE+ALU group). TGF, Transforming growth factor; Smad, mothers against decapentaplegic 




Cell surface receptors of TGFβ signaling are mainly 
classified into two subtypes: type I (TGFβRI) and type II 
(TGFβRII). Smad-dependent TGFβ signaling from 
cytoplasm to nucleus are primarily three Smad\isoforms 
in the Smad family, that is, Smad 2, 3 and 4. The binding 
of ligands to TGFβRII leads (TGFβRI) to phosphorylated 
Smad 2 and 3 which then bind to Smad 4 forming a 
trimeric complex and translocate into the nucleus. In  the 
nucleus, the Smad trimeric complex binds the Smad 
binding element (SBE) of target genes, regulating expres-
sion of TGFβ response genes directly or through 
recruiting other co-factors (co-activators or co-repressors) 
to target genes (Feng and Derynck, 2005; Liu and Feng, 
2010).  
A third class of Smads, negatively regulate TGF-β and 
bone morphogenetic protein (BMP) signaling by 
competing with R-Smads for binding to TβRI or targeting 
receptors to proteasomal degradation, therefore, are 
named the inhibitory Smads (I-Smads) (Imamura et al., 
1997; Hayashi et al., 1997; Ebisawa et al., 2001; Kavsak 
et al., 2000). Previous studies have demonstrated that 
there are three types of Smads: receptor-regulated 
(Smad 1, 2, 3, 5 and 8), inhibitory (Smad 6 and 7) and 
universal (Smad 4) types (Jiang et al., 2008; Massague 
and Wotton, 2000). 
In this study, we examined the effects of OVE+ALU-
induced chronic asthma on lung tissue using HE staining, 
histology of the HE-stained tissues showed a marked 
alteration in the experimental group as compared to the 
control group, that it means the model rats are success 
which means ovalbumin and aluminum hydroxide can 
induce the rat’s bronchial asthma. 




Table 2. Expression of TGF-β1 and Smad 2, 4 and 7 (mean ± SD, n = 6). 
 
Group TGF-β1 (ng/ml) Smad 2/NADPH Smad 4/NADPH Smad 7/NADPH 
Normal control 14.5 ± 2.2 33.52 ± 1.05 166.41 ± 15.29 102.29 ± 5.0 
Experimental 22.0 ± 2.1* 57.94 ± 33.02* 125.59 ± 47.58* 43.87 ± 5.19* 
 





In this study, we determined mRNA expression of TGF-
β1, Smad 2, 4 and 7. The results show that TGF-β1 and 
Smad 2 increased significantly in the experimental group 
when compared with the control group. There was no 
significant difference in Smad 4 mRNA expression 
between the control group and the experimental group. 
mRNA expression of Smad 7 was significantly decreased 
in the experimental group when compared with the 
control group. TGF-β and Smad protein expression in 
chronic asthma were detected by ELISA and western 
blotting. Protein expression of TGF-β in lung tissue 
increased significantly in the experimental group. Protein 
expression of Smad 2, 4 and 7 in lung tissue increased 
significantly in the experimental group. 
We showed that the TGF-β1/Smad signaling pathway 
was altered in the airway reconstruction in chronic 
asthma. Through the investigation of gene and protein 
expression of TGF-β1 and Smad 2, 4 and 7, we showed 
that TGF-β1 protein and mRNA were both significantly 
increased, thus indicating that TGF-β1 was activated. 
During TGF-β signal transduction, TGF-β receptor is 
initially activated. TGF-β and its receptor specifically 
recognize the Smad subgroup known as receptor-
activated Smads [R-Smads (Smad 2 and 3)] (Liu et al., 
2010). R-Smads are subsequently activated to form a 
complex consisting of R-Smads and Smad 4, the latter of 
which is a co-Smad. The Smads transcriptional complex 
translocate to the nucleus, where it binds to a certain 
domain of the target gene and causes gene expression, 
for example, in the genes it involved collagen production. 
In chronic asthma, up-regulation of TGF-β may activate 
the TGF-β receptor, which specifically recognizes the 
Smad subgroup. The TGF-β receptor then modulates the 
high expression of Smad 2, which coincides with the 
receptor-regulate. Excess collagen production can cause 
alveolar expansion verily, thus, leading to the occurrence 
of asthma. The role of Smad 7 in the TGF-β/Smad 
signaling pathway is the inhibition of R-Smads 
phosphorylation and the blocking of signal transduction, 
thus, terminating gene expression. In chronic asthma, 
Smad 7 expression is down-regulated; this causes the 
balance to be upset in order to promote the TGF-β/Smad, 
thus, signaling a pathway that can induce proliferation. 
Smad 4 forms a complex consisting of R-Smads in the 
TGF-β/Smad signaling pathway. In chronic asthma, Smad 
4 gene expression was not altered but protein expression 
was down-regulated. Further research is needed to 
investigate this observation. 
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